Thermo Fisher Scientific and Genovis, a  provider of enzyme products for biologic drug development, begin a collaborative research project to develop advanced end-to-end workflows for the preparation, characterization and monitoring of novel and complex biotherapeutics using liquid chromatography-mass spectrometry (LC-MS).

The alliance will leverage Thermo Fisher’s LC-MS technology with Genovis’ advanced enzyme-based sample preparation and analysis techniques to enable the development of robust, automation-ready, magnetic bead and chromatography-based workflows for the streamlined analysis of biotherapeutics. Thermo Fisher’s Global Customer Solution Centers will also help Genovis to determine optimal hardware/software configurations and suitable consumables for critical quality attribute (CQA) analysis of biotherapeutics during the research and development phase.

“With the shift toward large biological entities, companies are aiming to bring to market medicines with greater affinity and efficacy, but these medicines also present an additional level of analytical complexity,” said John Rontree, senior director, global marketing and strategy, pharmaceuticals and biopharmaceuticals, Thermo Fisher Scientific. “By collaborating with Genovis, we plan to develop comprehensive workflows that provide robust and advanced solutions for preparing and assessing complex biotherapeutics.”

“We are excited to work with Thermo Fisher Scientific to continue our goal toward more automated analytical workflows,” said Fredrick Olsson, chief executive officer at Genovis. “Through this collaboration we will be able to develop new products and workflows on world-class instrumentation together with experts from Thermo Fisher’s European Biopharma Customer Solution Center and serve the growing analytical needs of biopharma customers of both companies with meaningful innovations.”